Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial

P. Yudkin,M. Munafo,K. Hey,Sarah Roberts,S. Welch,E. Johnstone,M. Murphy,Siân-Elin Griffiths,R. Walton
DOI: https://doi.org/10.1136/bmj.38050.674826
2004-03-19
British Medical Journal
Abstract:The overall effectiveness of nicotine replacement therapy could be greater if the therapy were targeted at those most likely to respond. Variants of the dopamine D2 receptor ( DRD2 32806 C/T) have been implicated in the initiation and maintenance of smoking,1 2 and these variants may also be related to response to nicotine replacement therapy.3 Additionally, mechanisms of nicotine addiction may differ in men and women.4 With this evidence in mind, we examined whether the response to nicotine replacement therapy is modified by sex and genotype. A randomised controlled trial of nicotine patches in 1991-2 recruited 1686 heavy smokers (≥15 cigarettes a day).5 The participants wore patches for 12 weeks. Abstinence from smoking was confirmed at one week by expired carbon monoxide concentration ≤ 10 ppm, and at 12, 24, and 52 weeks by salivary cotinine concentration ≤ 20 ng/ml (89% of cases) or by expired carbon monoxide concentration ≤10 ppm. In 1999-2000, we contacted 1532 of the 1625 participants still alive; the mean …
What problem does this paper attempt to address?